Interpretation of the Keypoints and Updates on National Clinical Guideline for Stroke for the United Kingdom and Ireland (Edition 2023) —Ischemic Stroke
HAO Manjun1, CAO Zhixin1, LI Guangshuo1, XIONG Yunyun1,2,3
HAO Manjun, CAO Zhixin, LI Guangshuo, XIONG Yunyun. Interpretation of the Keypoints and Updates on National Clinical Guideline for Stroke for the United Kingdom and Ireland (Edition 2023) —Ischemic Stroke[J]. Chinese Journal of Stroke, 2023, 18(12): 1357-1364.
[1]MENON B K,BUCK B H,SINGH N,et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada(AcT):a pragmatic,multicentre,open-label,registry-linked,randomised,controlled,non-inferiority trial[J]. Lancet,2022,400(10347):161-169.
[2]WANG Y,LI S,PAN Y,et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events(TRACE-2):a phase 3,multicentre,open-label,randomised controlled,non-inferiority trial[J]. Lancet,2023,401(10377):645-654.
[3]POWERS W J,RABINSTEIN A A,ACKERSON T,et al. Guidelines for the early management of patients with acute ischemic stroke:2019 update to the 2018 guidelines for the early management of acute ischemic stroke:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke,2019,50(12):e344-e418[2023-07-05]. https://doi.org/10.1161/STR.0000000000000211.
[4]刘丽萍,周宏宇,段婉莹,等. 中国脑血管病临床管理指南(第2版)(节选)——第4章缺血性脑血管病临床管理推荐意见[J]. 中国卒中杂志,2023,18(8):910-933. LIU L P,ZHOU H Y,DUAN W Y,et al. Chinese stroke association guidelines for clinical management of cerebrovascular diseases(second edition)(excerpt)—chapter four clinical management of ischaemic cerebrovascular diseases[J]. Chin J Storke,2023,18(8):910-933.
[5]THOMALLA G,SIMONSEN C Z,BOUTITIE F,et al. MRI-guided thrombolysis for stroke with unknown time of onset[J]. N Engl J Med,2018,379(7):611-622.
[6]MA H,CAMPBELL B C V,PARSONS M W,et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke[J]. N Engl J Med,2019,380(19):1795-1803.
[7]ALBERS G W,CAMPBELL B C,LANSBERG M G,et al. Efficacy and safety of tenecteplase in patients with late-window acute ischaemic stroke and evidence of salvageable tissue:results from the phase Ⅲ TIMELESS trial[J/OL]. Eur Stroke J,2023,2_suppl(8):670-711[2023-07-05]. https://doi.org/10.1177/23969873231174267.
[8]YANG P F,ZHANG Y W,ZHANG L,et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med,2020,382(21):1981-1993.
[9]ZI W J,QIU Z M,LI F L,et al. Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke:the DEVT randomized clinical trial[J]. JAMA,2021,325(3):234-243.
[10]SUZUKI K,MATSUMARU Y,TAKEUCHI M,et al. Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke:the SKIP randomized clinical trial[J]. JAMA,2021,325(3):244-253.
[11]LECOUFFE N E,KAPPELHOF M,TREURNIET K M,et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke[J]. N Engl J Med,2021,385(20):1833-1844.
[12]FISCHER U,KAESMACHER J,STRBIAN D,et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke:an open-label,blinded-outcome,randomised non-inferiority trial[J]. Lancet,2022,400(10346):104-115.
[13]MITCHELL P J,YAN B,CHURILOV L,et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset:an open-label,blinded-endpoint,randomised non-inferiority trial[J]. Lancet,2022,400(10346):116-125.
[14]]MAJOIE C B,CAVALCANTE F,GRALLA J,et al. Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke:individual participant data meta-analysis of six randomised trials[J]. Lancet,2023,402(10406):965-974.
[15]YOSHIMURA S,SAKAI N,YAMAGAMI H,et al. Endovascular therapy for acute stroke with a large ischemic region[J]. N Engl J Med,2022,386(14):1303-1313.
[16]SARRAJ A,HASSAN A E,ABRAHAM M G,et al. Trial of endovascular thrombectomy for large ischemic strokes[J]. N Engl J Med,2023,388(14):1259-1271.
[17]HUO X C,MA G T,TONG X,et al. Trial of endovascular therapy for acute ischemic stroke with large infarct[J]. N Engl J Med,2023,388(14):1272-1283.
[18]LIU X F,DAI Q L,YE R D,et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion(BEST):an open-label,randomised controlled trial[J]. Lancet Neurol,2020,19(2):115-122.
[19]TAO C R,NOGUEIRA R G,ZHU Y Y,et al. Trial of endovascular treatment of acute basilar-artery occlusion[J]. N Engl J Med,2022,387(15):1361-1372.
[20]JOVIN T G,LI C H,WU L F,et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion[J]. N Engl J Med,2022,387(15):1373-1384.
[21]ZHAO Z A,QIU J,WANG L,et al. Intra-arterial tenecteplase is safe and may improve the first-pass recanalization for acute ischemic stroke with large-artery atherosclerosis:the BRETIS-TNK trial[J/OL]. Front Neurol,2023,14:1155269[2023-07-05]. https://doi.org/10.3389/fneur.2023.1155269.
[22]XIONG Y Y,CAMPBELL B C V,FISHER M,et al. Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events Ⅲ(TRACE Ⅲ):a randomised,phase Ⅲ,open-label,controlled trial[J/OL]. Stroke Vasc Neurol,2023,29:svn-2023-002310[2023-07-05]. http://dx.doi.org/10.1136/svn-2023-002310.